Bovine derived xenograft in combination with autogenous bone chips versus xenograft alone for the augmentation of bony dehiscences around oral implants: A randomized, controlled, split‐mouth clinical trial

Andy Temmerman,Simone Cortellini,Jeroen Van Dessel,Alexander De Greef,Wim Teughels,Marc Quirynen
DOI: https://doi.org/10.1111/clr.347_13509
2019-09-01
Clinical Oral Implants Research
Abstract:BackgroundAlthough the results of Type 2 placement with simultaneous contour augmentation are very beneficial, there still is debate about the need to combine autogenous bone chips with a graft material. Whereas the addition of autologous bone chips might increase the bone formation, the resorption of a xenograft is slightly inferior compared to the combination of a xenograft and autologous bone.Aim/HypothesisThe aim of the present study was to clinically and radiologically evaluate whether the use of a xenograft is not inferior to the use of a xenograft combined with autogenous bone chips for the treatment of bony dehiscences at implant placement.Material and MethodsThis study was designed as a randomized, controlled, clinical trial with split‐mouth design. Fourteen patients were enrolled in the present study, in need of bilateral implant placement with simultaneous GBR procedure to treat a bony dehiscence. At the control site the dehiscence was treated using a composite graft (50% autogenous bone + 50% xenograft). At the test site 100% xenograft was used. Both sites were covered with a resorbable collagen membrane and tension‐free closure was achieved. Dehiscences were measured clinically at implant placement and at re‐entry and abutment connection (4 months). CBCT were taken at immediately after implant placement and after 4 months. Defect reduction (horizontal and vertical) were compared between test and control sites, both clinically and radiographically.ResultsIn total 28 implants and 28 GBR procedures were performed in 14 patients (8 males and 6 females+ mean age‐ 54.6 year (range‐ 21–77 years)). One implant failed to osseointegrate (control group). On average the change in vertical defect height was 46.7% in the test‐group and 50.9% in the control group (P > 0.05). In 2 out of 14 sites (test group) and 3 out of 14 sites (control group) the vertical defect was totally resolved. The horizontal defect width at the implant shoulder change on average 40.5% in the test‐group and 40.9% in the control group (P > 0.05). On average a change in augmentation thickness (based on linear CBCT measurements) of 68.9% (test‐group) and 55.5% (control‐group) between implant placement and augmentation and abutment surgery was obtained at the implant shoulder (P > 0.05). Conclusion and Clinical ImplicationsWithin the limitations of the present randomized, controlled and clinical trial the use of autogenous bone chips as an adjunct to a xenograft in the treatment of solitary bony dehiscencies occurring during implant placement might be questionable. At implant shoulder level the augmentation thickness seems to be disappear after suturing and healing phase. Fixation of the graft might be of more importance than the use of autogenous bone chips.
engineering, biomedical,dentistry, oral surgery & medicine
What problem does this paper attempt to address?